Strategy:
M&A Advisory
Venture Building
Website:
Sector:
HealthTech
AI-based Diagnostics
Location:
UK & Canada
Date:
Currently open
Status:
Active
Contact:
Oliver Murphy
Kamil Kucharczyk
NutraTune, developed by MedBiome, is a precision microbiome nutrition platform addressing chronic diseases like Inflammatory Bowel Disease (IBD) and Alzheimer’s Disease (AD).
The solution combines a proprietary microbiome diagnostic test (RapidAIM™) with an AI-personalized prebiotic supplement to modulate gut health and reduce inflammation.
MedBiome’s technology is built on over 8 years of R&D and backed by USD 15M+ in non-dilutive funding. The platform’s efficacy has been validated through clinical studies, including a 50% reduction in IBD flare-up risk in pediatric patients.
The company is already revenue-generating through industrial B2B services and is preparing for a consumer launch in 2026, with a goal of surpassing USD 10M in revenues within 4 years at 60–70% gross margins.
MedBiome targets a multi-billion-dollar addressable market of over 4 million early-adopter patients in North America and Europe. Its business model leverages strong IP, biobanking assets, and a growing microbiome data flywheel.
Mansun Capital is supporting MedBiome in its USD 7–10M Series A round, enabling the company to scale NutraTune to consumer markets, expand AI-driven diagnostics, and grow its industrial partnerships in pharma and nutrition.